Close Menu
    Facebook X (Twitter) Instagram
    SciTechDaily
    • Biology
    • Chemistry
    • Earth
    • Health
    • Physics
    • Science
    • Space
    • Technology
    Facebook X (Twitter) Pinterest YouTube RSS
    SciTechDaily
    Home»Health»FDA Approves Breakthrough Treatment That Helps Children With Type 1 Diabetes Keep Producing Insulin
    Health

    FDA Approves Breakthrough Treatment That Helps Children With Type 1 Diabetes Keep Producing Insulin

    By University of Colorado AnschutzNovember 17, 2026No Comments5 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn WhatsApp Email Reddit
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email Reddit
    Diabetes Fasting Blood Sugar
    A newly approved treatment could change how doctors manage type 1 diabetes in children by slowing the immune attack on insulin-producing cells. Credit: Shutterstock

    For children with type 1 diabetes, managing blood sugar is a lifelong challenge, but a newly approved treatment offers hope of preserving their body’s ability to produce insulin.

    For children newly diagnosed with type 1 diabetes, insulin is essential for controlling blood sugar, but it cannot stop the immune system from destroying the cells that produce it. A newly approved treatment offers a way to slow that damage and preserve more of the body’s own insulin production. However, families have only a short window after diagnosis to consider the option.

    In June 2026, the U.S. Food and Drug Administration (FDA) expanded its approval of teplizumab to include children and adolescents ages 8 to 17 with newly diagnosed stage 3 type 1 diabetes. This is the stage when symptoms appear and insulin treatment becomes necessary. The expansion was granted through the FDA’s accelerated approval pathway, based on evidence that the drug helps preserve insulin production. Teplizumab was already approved for people ages 1 and older with stage 2 type 1 diabetes to delay progression to stage 3.

    Type 1 diabetes develops when the immune system attacks beta cells in the pancreas, which produce insulin to help the body use energy from food and regulate blood sugar. Some of these cells usually remain when symptoms first appear. Teplizumab targets the immune cells responsible for the damage, potentially extending the “honeymoon” period when patients still produce some insulin themselves.

    “Insulin is essential in stage 3 type 1 diabetes, but it doesn’t address the immune process that is destroying the cells that make insulin,” said Kimber Simmons, MD, MS, an associate professor of pediatrics at the University of Colorado Anschutz School of Medicine and a physician-scientist at the Barbara Davis Center for Diabetes. “Teplizumab gives us an opportunity to preserve some of the beta cells and insulin-producing capacity that a person still has. The goal is to intervene early enough to make a meaningful difference.”

    Teplizumab helps preserve insulin production

    Evidence supporting the expanded approval came from the PROTECT clinical trial, which involved 328 children and adolescents. After 78 weeks, participants who received teplizumab retained significantly more insulin-producing capacity than those given a placebo. Researchers measured this using C-peptide, a marker of how much insulin the body produces naturally.

    Nearly 95% of children treated with teplizumab maintained a clinically meaningful level of their own insulin production, compared with about 79% of those receiving placebo. Separate studies involving people with type 1 diabetes have linked higher C-peptide levels with fewer episodes of severe low blood sugar, reduced insulin requirements, and a lower risk of certain complications, including diabetic eye disease.

    Treatment must begin within eight weeks

    The timing of treatment is particularly important. Teplizumab must be started within eight weeks of diagnosis, while participants in PROTECT began treatment within six weeks. Earlier research also suggested that starting treatment sooner may produce stronger responses.

    Treatment involves two 12-day courses of daily intravenous infusions, typically six months apart. Potential side effects include rash, headache, nausea, and temporary reductions in lymphocytes, a type of white blood cell. More serious risks include cytokine release syndrome, an inflammatory reaction, infections, and viral reactivation. Experienced medical teams and careful monitoring are therefore necessary.

    Teplizumab does not cure type 1 diabetes or eliminate the need for insulin. Instead, it introduces another way to manage the disease by addressing the underlying immune process.

    Bringing teplizumab into everyday diabetes care

    To help clinicians and families navigate these decisions, Simmons led a national group of clinical trial investigators and pediatric diabetes specialists in developing practical guidance published in Diabetes Care. Supported by Breakthrough T1D, the guidance combines clinical trial evidence with experience in everyday patient care. It covers patient selection, potential benefits and risks, shared decision-making, safety monitoring, and treatment planning.

    Simmons, who also practices at Children’s Hospital Colorado, co-authored the published results of both PROTECT and PETITE-T1D, a study examining teplizumab in children younger than 8 with stage 2 type 1 diabetes.

    “Once a treatment is approved, the question becomes: How do we actually do this in the clinic?” said Simmons. “The way patients are treated in the real world doesn’t always line up perfectly with a clinical trial protocol. We wanted to give clinicians practical guidance so they can have informed conversations with families and make thoughtful, safe decisions.”

    The guidance also addresses a longstanding challenge in medicine: translating research advances into routine care.

    “Research shows that, on average, it takes 17 years for landmark medical breakthroughs to become widely adopted in routine clinical practice. Closing that gap is essential to getting the best science to people sooner,” said Breakthrough T1D Senior Vice President of Medical Affairs Anastasia Albanese-O’Neill, Ph.D., APRN, CDCES. “Breakthrough T1D is focused on efforts that will close this gap in a way that is safe and supports shared decision-making between clinicians and families. This new clinical guidance serves as an important tool that will help guide timely care for children with a new stage 3 type 1 diabetes diagnosis. We’re grateful to the leaders who provided their expertise and time to develop it.”

    The authors emphasize that teplizumab should be incorporated into existing diabetes care rather than delivered through an entirely separate treatment system.

    “We don’t want to create a separate pathway that fragments care,” said Simmons. “This is an opportunity to be thoughtful about how we use a new therapy while keeping the whole patient in view. Our specialty needs to stay focused on providing the best coordinated care we can.”

    Reference: “Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes” by Kimber M. Simmons, Adriana Weinberg, Emily Breidbart, Carla Demeterco-Berggren, Stephen Gitelman, Kevan C. Herold, Shideh Majidi, Daniel Moore, Amara Ogbonnaya-Whittlesey, Neha Patel, Jennifer L. Sherr, Emily K. Sims, Kupper Wintergerst and Michael J. Haller, 11 November 2026, Diabetes Care.
    DOI: 10.2337/dci26-0061

    Never miss a breakthrough: Join the SciTechDaily newsletter.
    Follow us on Google and Google News.

    Diabetes Immunotherapy Insulin Pediatrics University of Colorado Anschutz Medical Campus
    Share. Facebook Twitter Pinterest LinkedIn Email Reddit

    Related Articles

    How Migraines Protect Against Type 2 Diabetes

    Scientists Help Solve Insulin Puzzle – Could Enhance Treatments for Diabetes and Cancer

    ADHD, Bipolar, and Aggressive Behavior May Be Driven by High Fructose Intake

    New Ultrafast Insulin for Faster Management of Blood Sugar in Diabetes

    Researchers Develop a New Ultrafast Insulin for Management of Blood Sugar in Diabetes

    Weight Loss Enhanced in Obese Children by Probiotic Supplements

    Despite Proven Success at Preventing Cancer, Physicians Report High Refusal Rates for HPV Vaccine

    High Glucose Levels During Pregnancy Affects the Baby’s Heart

    Engineered Insulin Stays in Bloodstream, Offers Better Diabetes Control

    Leave A Reply Cancel Reply

    • Facebook
    • Twitter
    • Pinterest
    • YouTube

    Don't Miss a Discovery

    Subscribe for the Latest in Science & Tech!

    Trending News

    Scientists Uncover a Bizarre Quantum Effect Where Time Could Flow at Different Speeds Simultaneously

    James Webb Telescope Reveals a Giant Planet That Was Hiding in Plain Sight

    Scientists Just Challenged a 50-Year-Old Theory About How Evolution Works

    Researchers Turn Moon Dust Into LEGO-Like Bricks That Could Build Future Lunar Bases

    Powerful New Weight-Loss Drug Could Change How Millions Treat Painful Knee Arthritis

    A 3-Million-Year-Old Fossil Is Turning the Story of Human Evolution Upside Down

    A Simple Pill Could Cure a Common Cause of High Blood Pressure

    A 6-Million-Year-Old Whale Had a Face So Strange Scientists Thought It Was Crushed

    Follow SciTechDaily
    • Facebook
    • Twitter
    • YouTube
    • Pinterest
    • Newsletter
    • RSS
    SciTech News
    • Biology News
    • Chemistry News
    • Earth News
    • Health News
    • Physics News
    • Science News
    • Space News
    • Technology News
    Recent Posts
    • FDA Approves Breakthrough Treatment That Helps Children With Type 1 Diabetes Keep Producing Insulin
    • Not All Physical Activity Protects Your Brain, Scientists Warn
    • Arctic Bacteria May Be Using Sunlight and CO2 in a Way Scientists Never Expected
    • Earth’s Ancient Oceans May Have Fooled Scientists About the Rise of Oxygen
    • Rewriting History: New Research Reveals Ancient Iron Age King May Have Been a Woman
    Copyright © 1998 - 2026 SciTechDaily. All Rights Reserved.
    • Science News
    • About
    • Contact
    • Editorial Board
    • Privacy Policy
    • Terms of Use

    Type above and press Enter to search. Press Esc to cancel.